Cargando…
Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/ https://www.ncbi.nlm.nih.gov/pubmed/35769314 http://dx.doi.org/10.1177/23743735221105673 |
_version_ | 1784736164233609216 |
---|---|
author | Razonable, Raymund R Ganesh, Ravindra Bishop, Rachel K Culbertson, Tracy L Destro Borgen, Molly Hedin, Michelle C Hopkins, Laura H Jackson, Tammy A Larsen, Jennifer J Matoush, Jennifer A Moehnke, Darcie E Olson, Shelly M Peterson, Kellie M Rosedahl, Jordan Philpot, Lindsey M |
author_facet | Razonable, Raymund R Ganesh, Ravindra Bishop, Rachel K Culbertson, Tracy L Destro Borgen, Molly Hedin, Michelle C Hopkins, Laura H Jackson, Tammy A Larsen, Jennifer J Matoush, Jennifer A Moehnke, Darcie E Olson, Shelly M Peterson, Kellie M Rosedahl, Jordan Philpot, Lindsey M |
author_sort | Razonable, Raymund R |
collection | PubMed |
description | Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19. |
format | Online Article Text |
id | pubmed-9234828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-92348282022-06-28 Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 Razonable, Raymund R Ganesh, Ravindra Bishop, Rachel K Culbertson, Tracy L Destro Borgen, Molly Hedin, Michelle C Hopkins, Laura H Jackson, Tammy A Larsen, Jennifer J Matoush, Jennifer A Moehnke, Darcie E Olson, Shelly M Peterson, Kellie M Rosedahl, Jordan Philpot, Lindsey M J Patient Exp Research Article Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19. SAGE Publications 2022-06-23 /pmc/articles/PMC9234828/ /pubmed/35769314 http://dx.doi.org/10.1177/23743735221105673 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Article Razonable, Raymund R Ganesh, Ravindra Bishop, Rachel K Culbertson, Tracy L Destro Borgen, Molly Hedin, Michelle C Hopkins, Laura H Jackson, Tammy A Larsen, Jennifer J Matoush, Jennifer A Moehnke, Darcie E Olson, Shelly M Peterson, Kellie M Rosedahl, Jordan Philpot, Lindsey M Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 |
title | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for
Mild to Moderate Coronavirus Disease-2019 |
title_full | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for
Mild to Moderate Coronavirus Disease-2019 |
title_fullStr | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for
Mild to Moderate Coronavirus Disease-2019 |
title_full_unstemmed | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for
Mild to Moderate Coronavirus Disease-2019 |
title_short | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for
Mild to Moderate Coronavirus Disease-2019 |
title_sort | patient perspectives on anti-spike monoclonal antibody therapy for
mild to moderate coronavirus disease-2019 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234828/ https://www.ncbi.nlm.nih.gov/pubmed/35769314 http://dx.doi.org/10.1177/23743735221105673 |
work_keys_str_mv | AT razonableraymundr patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT ganeshravindra patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT bishoprachelk patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT culbertsontracyl patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT destroborgenmolly patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT hedinmichellec patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT hopkinslaurah patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT jacksontammya patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT larsenjenniferj patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT matoushjennifera patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT moehnkedarciee patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT olsonshellym patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT petersonkelliem patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT rosedahljordan patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT philpotlindseym patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 |